Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.64 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.59 |
| ▸ | CIT | O14578 | 4/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376209 | 1.00 | AAK1 (0.64) | AAK1LARS1CITTAAR1MEN1 | |
| Hydrochloric Acid SCHEMBL10788646 | 0.98 | AAK1 (0.62) | AAK1LARS1CITTAAR1MEN1 | |
| Acetic Acid SCHEMBL8935166 | 0.97 | AAK1 (0.61) | AAK1LARS1CITTAAR1MEN1 | |
| SCHEMBL7409778 | 0.85 | TAAR1 (0.50) | AAK1LARS1CITTAAR1MEN1 | |
| SCHEMBL11493006 | 0.85 | AAK1 (0.67) | AAK1LARS1CITMAPT | |
| SCHEMBL6518397 | 0.85 | AAK1 (0.67) | AAK1CITMAPT | |
| SCHEMBL9490663 | 0.85 | AAK1 (0.67) | AAK1LARS1CITMAPT | |
| SCHEMBL10797393 | 0.85 | AAK1 (0.67) | AAK1LARS1CITMAPT | |
| SCHEMBL17152486 | 0.83 | AAK1 (0.65) | AAK1CITMEN1KMT2AALDH1A1 | |
| SCHEMBL6518395 | 0.83 | AAK1 (0.65) | AAK1LARS1CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-116370448-A | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| CN-110809467-B | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-3364958-B1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20180333381-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-11-22 | — | — | US | disclosed |
| WO-2018200625-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-10100066-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3364958-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-0740652-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019956-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | AAK1 1942/4885LARS1 3423/4885CIT 351/4885 |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | AAK1 2350/4885LARS1 2380/4885CIT 356/4885 |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | AAK1 2350/4885LARS1 2380/4885CIT 356/4885 |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, HIRA, HRH1 | AAK1 1932/4885LARS1 1694/4885CIT 161/4885 |
| US-10100066-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | AAK1 2350/4885LARS1 2380/4885CIT 356/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | AAK1 2350/4885LARS1 2380/4885CIT 356/4885 |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | AAK1 2350/4885LARS1 2380/4885CIT 356/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | AAK1 2350/4885LARS1 2380/4885CIT 356/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | AAK1 2350/4885LARS1 2380/4885CIT 356/4885 |
| US-20180333381-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | AAK1 2350/4885LARS1 2380/4885CIT 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.